The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract 2012; 2012: 743193.Mitri Z, Constantine T, O'Regan R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2012...
[7]Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast ...
[17]Kim MH, Kim GM, Kim JH, Kim JY, Park HS, Park S, et al.. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. Breast Canc...
regulators, or estrogen suppressive therapies23. As for breast cancers that are both ER+ and HER2+, inhibition of HER2 alone enables potential compensatory escape pathways due to the bi-directional signaling (i.e., crosstalk) between these receptor signaling pathways, which can result in resistan...
Herceptin is approved for the treatment of adults with early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes,...
21. Wang X, Ling F, Gao J, et al. A multicenter, open-label, single-arm, non-interventional real-world study to investigate the treatment patierns of neratinib in Human Epidermal Growth Factor Receptor 2 positive (HER2+) early breast cancer (EBC) in China: NER-Tree study. ESMO Open....
[14] Hua X, Bi XW, Zhao JL, et al. Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clin Cancer Res. 2022 Feb 15;28(4):637-645....
[5] Eggemann H, Ignatov T, Burger E et al (2015) Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer 22:725–733. [6] Howlader N, Cronin KA, Kurian AW et al (2018) Differences in breast cancer survival by molecular subtypes in...
Patients with small, human epidermal growth factor receptor 2 (HER2)–positive breast tumors treated with adjuvant paclitaxel and trastuzumab showed persistently high rates of disease-free survival (DFS) after a median follow-up of 6.5 years, reported a secondaryanalysisinJournal of Clinical On...
This work demonstrated that HER2 amplification is a prognostic factor and predictive of outcomes in breast cancer. Article CAS Google Scholar Giordano, S. H. et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J. Clin. ...